265 related articles for article (PubMed ID: 20148560)
1. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
Culhane JC; Wang D; Yen PM; Cole PA
J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
3. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
4. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
Schmidt DM; McCafferty DG
Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
[TBL] [Abstract][Full Text] [Related]
5. LSD1 Histone Demethylase Assays and Inhibition.
Hayward D; Cole PA
Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
[TBL] [Abstract][Full Text] [Related]
6. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
7. A mechanism-based inactivator for histone demethylase LSD1.
Culhane JC; Szewczuk LM; Liu X; Da G; Marmorstein R; Cole PA
J Am Chem Soc; 2006 Apr; 128(14):4536-7. PubMed ID: 16594666
[TBL] [Abstract][Full Text] [Related]
8. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1.
Szewczuk LM; Culhane JC; Yang M; Majumdar A; Yu H; Cole PA
Biochemistry; 2007 Jun; 46(23):6892-902. PubMed ID: 17511474
[TBL] [Abstract][Full Text] [Related]
10. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
[TBL] [Abstract][Full Text] [Related]
11. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
13. Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors.
Li ZR; Wang S; Yang L; Yuan XH; Suo FZ; Yu B; Liu HM
Eur J Med Chem; 2019 Mar; 166():432-444. PubMed ID: 30739825
[TBL] [Abstract][Full Text] [Related]
14. A selective phenelzine analogue inhibitor of histone demethylase LSD1.
Prusevich P; Kalin JH; Ming SA; Basso M; Givens J; Li X; Hu J; Taylor MS; Cieniewicz AM; Hsiao PY; Huang R; Roberson H; Adejola N; Avery LB; Casero RA; Taverna SD; Qian J; Tackett AJ; Ratan RR; McDonald OG; Feinberg AP; Cole PA
ACS Chem Biol; 2014 Jun; 9(6):1284-93. PubMed ID: 24707965
[TBL] [Abstract][Full Text] [Related]
15. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
[TBL] [Abstract][Full Text] [Related]
16. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.
El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H
Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
[TBL] [Abstract][Full Text] [Related]
18. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
19. Human histone demethylase LSD1 reads the histone code.
Forneris F; Binda C; Vanoni MA; Battaglioli E; Mattevi A
J Biol Chem; 2005 Dec; 280(50):41360-5. PubMed ID: 16223729
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]